SMILE (Small Incision Lenticule Extraction) in the DoD (Department of Defense)

Not Applicable

Recruiting

• Conditions: Astigmatism; Myopia
• Interventions: Device: Visumax spherocylindrical treatment

• Registration Number: NCT04072289
• Lead Sponsor: United States Naval Medical Center, San Diego

Brief Summary

The Use of the VisuMaxTM Femtosecond Laser Small-Incision Lenticule Extraction (SMILE) Procedure for the Correction of Myopia with or without Astigmatism study is a prospective, non-randomized, multicenter clinical study that will be conducted by the Navy Refractive Surgery Center, Naval Medical Center San Diego, CA in collaboration with the U.S. Air Force 59th Medical Wing, Wilford Hall Eye Center, TX, and the U.S. Army Warfighter Refractive Eye Surgery Program and Research Center, Fort Belvoir Community Hospital, VA.

Detailed Description

Prospective, multicenter, open-label, non-randomized clinical trial with bilateral commercial treatment for FDA approved indications and unilateral treatments for investigational refractive errors. Data from each treated eye of subjects will be treated independently. Monovision treatments and retreatments of the study eye will not be allowed during the course of the study. Successful bilateral treatment is required for performance based testing and patient reported outcome testing. Subjects will be randomized into the 0.25 and 0.50 sphere only and spherical cylinder bins using a sequential alternating randomization with an equal number assigned to both bins. Other subjects will be assigned to the bins they qualify for as they are enrolled into the study. Appointments are given to patients requesting refractive surgery randomly.

Three military sites in the U.S.A.: Navy Refractive Surgery Center, Naval Medical Center San Diego, CA in collaboration with the U.S. Air Force 59th Medical Wing, Wilford Hall Eye Center, TX, and the U.S. Army Warfighter Refractive Eye Surgery Program and Research Center, Fort Belvoir Community Hospital, VA.

Study Timeline

• Study First Submitted: 2019-03-11
• Study Start: 2019-05-01
• Study First Submitted QC: 2019-08-26
• Study First Posted: 2019-08-28
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-14
• Last Update Posted: 2022-04-15
• Primary Completion: 2023-09
• Study Completion: 2024-09

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

1. Male and female subjects age 22 years of age and older either active duty or dependents who are eligible for care;

2. Myopia from ≥ 0 D to ≤ -10.00 D with ≤ -3.00 D cylinder and MRSE ≥ -1.00 D to

   ≤ -11.50 D in the eye(s) to be treated;

3. A stable refraction for the past year, as demonstrated by a change in MRSE of ≤ 0.50 D in the eyes to be treated;

4. A difference between cycloplegic and manifest refractions of

   ≤ 0.75 D spherical equivalent in both eye(s);

5. UCVA 2 lines worse than BCVA in the treated eye(s);

6. BSCVA at least 20/20 in the treated eye(s);

7. Discontinue use of contact lenses for at least 4 weeks (for hard lenses) or 2 weeks (for soft lenses) prior to the preoperative examination, and through entire study. The subject shall not be considered a contact lens wearer if they are not wearing hard contact lenses for 4 weeks or soft contact lenses for 2 weeks.

8. All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as determined by MRSE, on two consecutive examinations at least 7 days apart, in the eye(s) to be treated;

9. Central corneal thickness of at least 500 microns in the both eye(s);

10. Willing and able to return for scheduled follow-up examinations;

11. Able to provide written informed consent and follow study instructions in English.

12. Permission of the Commanding Officer for active duty subjects to receive refractive surgery and participate in the study.

Exclusion Criteria

1. Manifest cylinder of more than -3.00 D;
2. Estimated treatment depth is less than 250 microns from the corneal endothelium;
3. Eye to be treated is targeted for monovision;
4. Keratometry readings via Sim-K values less than 40.00 D;
5. Abnormal corneal topographic findings, e.g. keratoconus, pellucid marginal degeneration in either eye;
6. History of or current anterior segment pathology, including cataracts in the eye to be treated;
7. Clinically significant dry eye syndrome unresolved by treatment in either eye;
8. Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease in the either eye;
9. Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect) in either eye;
10. Irregular or unstable (distorted/not clear) corneal mires on central keratometry images in either eye;
11. History of ocular herpes zoster or herpes simplex keratitis;
12. Deep orbits, strong blink, anxiety, pterygium, or any other finding suggesting difficulty in achieving or maintaining suction;
13. Difficulty following directions or unable to fixate;
14. Previous intraocular or corneal surgery of any kind in the eye to be treated, including any type of surgery for either refractive or therapeutic purposes;
15. History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP > 21 mmHg in either eye;
16. History of diabetes, diagnosed autoimmune disease, connective tissue disease or clinically significant atopic syndrome;
17. Immunocompromised or requires chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing;
18. History of known sensitivity to planned study medications;
19. Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation;
20. Pregnant or lactating;
21. Anyone who has the potential to deploy or relocate during the follow-up period.
22. Systemic Medications that may confound the outcome of the study or increase risk to the subject, including but not limited to steroids, antimetabolites, etc.
23. Evidence of retinal vascular disease.
24. Glaucoma suspects by exam findings or family history.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Low cylinder (treatment)	Visumax spherocylindrical treatment	0.25D and 0.50D cylinder treatments will be measured and treated by the laser.

Primary Outcome Measures

Name	Time	Method
Measured postoperative refractive sphere and cylinder	12 months	manifest refraction spherical equivalent and manifest refractive cylinder refraction
Measured distance visual acuity	12 months	uncorrected visual acuity of 20/40 or better

Secondary Outcome Measures

Name	Time	Method
Measured difference in manifest refraction between 2 postoperative visits	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval	95% of eyes \<1.00D of MRSE change at latter of 2 postop refractions
Calculated decreased rate of change in manifest refraction	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval	mean rate of change of MRSE decreases monotonically over time
Measured refractive cylinder	12 months	incidence of induced cylinder \>2D
Calculated rate of change in manifest refraction	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval	mean rate of change of MRSE \<0.5D/year (0.04D/mo)
Incidence of patient reported visual phenomena	12 months	incidence of patient subjective symptoms
Measured contrast sensitivity	12 months	change in contrast sensitivity from preop to postop
Measured best corrected visual acuity (method 2)	12 months	incidence of loss of \>2 lines of best spectacled corrected visual acuity
Calculated stable rate of change in manifest refraction	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval	95% CI for the mean rate of change includes zero
Measured best corrected visual acuity (method 1)	12 months	incidence of best spectacled correction worse than 20/40
Incidence of adverse events	12 months	incidence of adverse events

Trial Locations

Locations (1)

Navy Warfighter Refractive Surgery Center; 🇺🇸 San Diego, California, United States